frontiers in psychiatry-360期刊网

您当前的位置: 首页 > SCI文献 > Frontiers in psychiatry

Frontiers in psychiatry 日本以家庭为基础治疗强迫症的评价: 一项先导随机对照试验。

影响因子：5.435 DOI：10.3389/fpsyt.2019.00932

作者： Kobayashi Y,Kanie A,Nakagawa A,Takebayashi Y,Shinmei I,Nakayama N,Yamaguchi K,Nakayama C,Hirabayashi N,Mimura M,Horikoshi M 发表时间：2020-02-04 15:38:28

from：《Frontiers in Psychiatry》

keywords： Kobayashi YKanie ANakagawa ATakebayashi YShinmei INakayama NYamaguchi KNakayama CHirabayashi NMimura MHorikoshi M

关键词：暴露反应预防以家庭为基础的治疗强迫症随机对照试验治疗

Abstract

:Objective: Although family involvement in the treatment of obsessive-compulsive disorder (OCD) produces a reduction in OCD symptoms and has significant effects on global functioning, few studies have focused on family intervention as part of OCD treatment in Japan. This study aims to examine the feasibility and efficacy of the family-based exposure and response prevention (FERP) program for adult patients with OCD and their family members. Design: Randomized controlled pilot study. Methods: A total of 18 outpatients aged 18-65 years with a primary diagnosis of OCD and one family member of each patient were randomized to an intervention group or a control group (1:1). The intervention group received the FERP program, which consisted of 16 weekly face-to-face cognitive behavioral therapy (CBT) sessions, including eight joint sessions with family members, in addition to treatment-as-usual (TAU). The control group received TAU alone. The primary outcome was the alleviation of OCD symptoms, as measured by changes in the total Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score from baseline to posttreatment. Analyses were provided on an intention-to-treat basis, and linear mixed models were used to test for significant group differences. Results: After 16 weeks, patients allocated to the FERP program showed improvement in OCD symptom severity, as measured by the total change score of the Y-BOCS (Hedges' g = -1.58), as compared to the control group. Two patients (22.2%) in the FERP group reached remission, and five patients (55.6%) in the FERP group achieved treatment response. Clinical global improvement measured by the FAS-SR scores, K6 scores, and CGI-S scores was also observed (Hedges' g = -1.35, -1.25, and -1.26, respectively) in the FERP group as compared to the control group. The dropout rate from the study was low (n = 2, 11.8%), and no adverse events were reported in the FERP group. Conclusion: Our results suggest that FERP may be an effective program for reducing patients' OCD symptoms. Clinical Trial Registration: www.umin.ac.jp/ctr/, identifier UMIN000021763.

摘要

目的: 虽然家庭参与强迫症 (OCD) 的治疗会减少 OCD 症状，并对全球功能有显著影响, 在日本，很少有研究将家庭干预作为强迫症治疗的一部分。本研究旨在检验以家庭为基础的暴露和反应预防 (FERP) 项目对成年强迫症患者及其家庭成员的可行性和疗效。设计: 随机对照初步研究。方法: 将 18 例 18 ~ 65 岁初次诊断为强迫症的门诊患者和每例患者的 1 名家属随机分为干预组和对照组 (1:1)。干预组接受了 FERP 项目，该项目由 16 次每周面对面认知行为治疗 (CBT) 会议组成，包括 8 次与家庭成员的联合会议, 除了治疗照常 (TAU)。对照组单纯接受 TAU 治疗。主要结局是 OCD 症状的缓解，通过耶鲁-布朗强迫量表 (Y-BOCS) 总分从基线到治疗后的变化来衡量。在意向治疗的基础上提供分析，并使用线性混合模型检验显著的组间差异。结果: 16 周后，根据 Y-BOCS 的总变化评分 (hedgs 'g =-1.58)，分配到 FERP 程序的患者表现出 OCD 症状严重程度的改善, 与对照组相比。FERP 组有 2 例患者 (22.2%) 达到缓解，FERP 组有 5 例患者 (55.6%) 达到治疗反应。通过 FAS-SR 评分、 K6 评分和 CGI-S 评分测量的临床整体改善也被观察到 (hedgs 的 g 分别为-1.35 、-1.25 和-1.26) 在 FERP 组与对照组相比。研究的退出率较低 (n = 11.8%)，FERP 组未报告不良事件。结论: 我们的结果表明，FERP 可能是减少患者 OCD 症状的有效方案。临床试验注册: www.umin.ac.jp/ctr/，标识符 UMIN000021763.

期刊介绍

《Frontiers in Psychiatry》 (点击进入期刊详情)

英文简介 : Frontiers in Psychiatry

中文简介 : （来自Google、百度翻译）精神病学前沿

CIRCULATION RESEARCH 期刊中科院评价数据

新中科院分区

大类(学科)	小类(学科)	学科排名
医学	PSYCHIATRY (精神病学)	45/142

新发布的期刊年发文量

年度总发文量	年度论文发表量	年度综述发表量
277	212	65

总被引频次 :4605

特征因子 : 0.013910

影响因子趋势图

相关文献

Neuroendocrinology

影响因子：5.24 DOI：10.1159/000505921 来源期刊：PubMed

作者：Izakova L,Hlavacova N,Segeda V,Kapsdorfer D,Morovicsova E,Jezova D 发表时间：2020-02-03 03:17:09

Brain, behavior, and immunity

影响因子：6.09 DOI：10.1016/j.bbi.2020.01.011 来源期刊：PubMed

作者：Sun Y,Drevets W,Turecki G,Li QS 发表时间：2020-02-03 03:19:22

Pharmacology, biochemistry, and behavior

影响因子：2.87 DOI：10.1016/j.pbb.2020.172859 来源期刊：PubMed

作者：Ahmad SF,Ansari MA,Nadeem A,Bakheet SA,Alqahtani F,Alhoshani AR,Alasmari F,Alsaleh NB,Attia SM 发表时间：2020-02-03 03:19:22

The Journal of clinical investigation

影响因子：10.49 DOI：10.1172/JCI130808 来源期刊：PubMed

作者：Gerhard DM,Pothula S,Liu RJ,Wu M,Li XY,Girgenti MJ,Taylor SR,Duman CH,Delpire E,Picciotto M,Wohleb ES,Duman RS 发表时间：2020-02-03 03:20:40

Schizophrenia bulletin

影响因子：6.60 DOI：10.1093/schbul/sbz129 来源期刊：PubMed

作者：Levitt JJ,Nestor PG,Kubicki M,Lyall AE,Zhang F,Riklin-Raviv T,O Donnell LJ,McCarley RW,Shenton ME,Rathi Y 发表时间：2020-02-03 03:20:40

Molecular psychiatry

影响因子：9.56 DOI：10.1038/s41380-020-0649-0 来源期刊：PubMed

作者：Li C,Meng F,Garza JC,Liu J,Lei Y,Kirov SA,Guo M,Lu XY 发表时间：2020-02-03 03:20:41

The Journal of neuroscience : the official journal of the Society for Neuroscience

影响因子：5.83 DOI：10.1523/JNEUROSCI.0786-19.2019 来源期刊：PubMed

作者：Torretta S,Rampino A,Basso M,Pergola G,Di Carlo P,Shin JH,Kleinman JE,Hyde TM,Weinberger DR,Masellis R,Blasi G,Pennuto M,Bertolino A 发表时间：2020-02-03 03:20:44

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

影响因子：6.22 DOI：10.1038/s41386-020-0614-2 来源期刊：PubMed

作者：Chadha R,Meador-Woodruff JH 发表时间：2020-02-03 03:20:47

BMC medical genetics

影响因子：1.91 DOI：10.1186/s12881-019-0946-0 来源期刊：PubMed

作者：Poisson A,Chatron N,Labalme A,Fourneret P,Ville D,Mathieu ML,Sanlaville D,Demily C,Lesca G 发表时间：2020-02-03 03:28:46

Frontiers in Neuroscience

影响因子：3.99 DOI：10.3389/fnins.2020.00050 来源期刊：Doaj

作者：Ying Yang,Dao-min Zhu,Dao-min Zhu,Dao-min Zhu,Cun Zhang,Yu Zhang,Yu Zhang,Yu Zhang,Chunli Wang,Biao Zhang,Wenming Zhao,Jiajia Zhu,Yongqiang Yu 发表时间：2020-02-03 03:44:07

服务推荐

基础SCI服务

医学领域资深专家团队

临床科研服务

一对一跟进，沉淀是辅导

课题基金服务

创新思路，真实数据

SCI论文翻译润色

母语化翻译润色